Scholarlink

Background <p>A position paper released by the European Association of Nuclear Medicine emphasised the need for multidisciplinary engagement to establish dosimetry-based personalised treatment in Radionuclide therapy (RNT). The uncertainty analysis results often ignored in routine clinical practice should be incorporated into the dose calculations to improve the efficacy and accuracy of treatment. In this study, patients with haematological malignancies undergoing radioimmunotherapy were evaluated. Our study aimed to calculate the uncertainties associated with each parameter of the single time point (STP) dosimetry chain and compare the with multiple time points (MTP) in the bone marrow and liver results.</p> Methods <p>28 patients received an intravenous injection of <sup>111</sup>In-besilesomab (0.17 ± 0.01GBq) for pre-therapeutic dosimetry and were subsequently treated with <sup>90</sup>Y-besilesomab(2.43 ± 0.53GBq). A dosimetry analysis was performed on bone marrow (BM) and liver with MTP and STP. We investigated the uncertainty in population mean effective half-life, volume, recovery coefficient, counts, measured activity, fitting parameters, time-integrated-activity, S-factors, and absorbed dose (AD) for a group of patients.</p> Results <p>The mean absorbed dose per unit administered activity (DpA) to BM was 5.8 ± 1.7 mGy/MBq with MTP and 5.8 ± 1.6 mGy/MBq with STP, and to the liver was 2.9 ± 1.9 mGy/MBq with MTP and 3.1 ± 2.4 mGy/MBq with STP. The mean fractional uncertainty associated with total absorbed dose to BM was 13.18 ± 3.46% with MTP and 18.75 ± 3.22% with STP, and to liver was 5.77 ± 3.13% with MTP and 49.78 ± 25.36% with STP. A moderate positive relationship (R<sup>2</sup> = 0.7) was noted between post-injection acquisition time and AD uncertainty with STP for BM, whereas a strong positive relationship (R<sup>2</sup> = 1) was noted for the liver.</p> Conclusion <p>The absorbed dose uncertainty in STP was significantly higher compared to the MTP. Incorporating the uncertainty analysis for STP dosimetry parameters in routine clinical practice is strongly recommended. The accuracy in the acquisition time, population-based half-life and fitting function for time activity curve is vital for minimising uncertainty in STP dosimetry, which is less time-consuming and easier to implement in clinical practice than MTP.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Uncertainty analysis of single-time-point organ dosimetry compared with the multi-time-point method in radioimmunotherapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月2日

查看全文
  • Amit Nautiyal,
  • Gemma Lewis,
  • Jonathan I. Gear,
  • Kim Orchard,
  • Matthew J. Guy,
  • Sofia Michopoulou

摘要

Background

A position paper released by the European Association of Nuclear Medicine emphasised the need for multidisciplinary engagement to establish dosimetry-based personalised treatment in Radionuclide therapy (RNT). The uncertainty analysis results often ignored in routine clinical practice should be incorporated into the dose calculations to improve the efficacy and accuracy of treatment. In this study, patients with haematological malignancies undergoing radioimmunotherapy were evaluated. Our study aimed to calculate the uncertainties associated with each parameter of the single time point (STP) dosimetry chain and compare the with multiple time points (MTP) in the bone marrow and liver results.

Methods

28 patients received an intravenous injection of 111In-besilesomab (0.17 ± 0.01GBq) for pre-therapeutic dosimetry and were subsequently treated with 90Y-besilesomab(2.43 ± 0.53GBq). A dosimetry analysis was performed on bone marrow (BM) and liver with MTP and STP. We investigated the uncertainty in population mean effective half-life, volume, recovery coefficient, counts, measured activity, fitting parameters, time-integrated-activity, S-factors, and absorbed dose (AD) for a group of patients.

Results

The mean absorbed dose per unit administered activity (DpA) to BM was 5.8 ± 1.7 mGy/MBq with MTP and 5.8 ± 1.6 mGy/MBq with STP, and to the liver was 2.9 ± 1.9 mGy/MBq with MTP and 3.1 ± 2.4 mGy/MBq with STP. The mean fractional uncertainty associated with total absorbed dose to BM was 13.18 ± 3.46% with MTP and 18.75 ± 3.22% with STP, and to liver was 5.77 ± 3.13% with MTP and 49.78 ± 25.36% with STP. A moderate positive relationship (R2 = 0.7) was noted between post-injection acquisition time and AD uncertainty with STP for BM, whereas a strong positive relationship (R2 = 1) was noted for the liver.

Conclusion

The absorbed dose uncertainty in STP was significantly higher compared to the MTP. Incorporating the uncertainty analysis for STP dosimetry parameters in routine clinical practice is strongly recommended. The accuracy in the acquisition time, population-based half-life and fitting function for time activity curve is vital for minimising uncertainty in STP dosimetry, which is less time-consuming and easier to implement in clinical practice than MTP.